###begin article-title 0
###xml 21 27 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNASEL</italic>
Germline Mutation in RNASEL Predicts Increased Risk of Head and Neck, Uterine Cervix and Breast Cancer
###end article-title 0
###begin p 1
Conceived and designed the experiments: CW LH ER MB KD. Performed the experiments: BM ER MB KD. Analyzed the data: CW BM LH ER MB KD. Contributed reagents/materials/analysis tools: JO LH MN. Wrote the paper: LH. Other: Contributed to the manuscript: CW BM.
###end p 1
###begin title 2
The Background
###end title 2
###begin p 3
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNASEL</italic>
###xml 180 186 180 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNASEL</italic>
Ribonuclease L (RNASEL), encoding the 2'-5'-oligoadenylate (2-5A)-dependent RNase L, is a key enzyme in the interferon induced antiviral and anti-proliferate pathway. Mutations in RNASEL segregate with the disease in prostate cancer families and specific genotypes are associated with an increased risk of prostate cancer.
###end p 3
###begin p 4
###xml 13 33 <span type="species:ncbi:10566">human papillomavirus</span>
###xml 35 38 <span type="species:ncbi:10566">HPV</span>
###xml 159 162 <span type="species:ncbi:10566">HPV</span>
###xml 208 233 <span type="species:ncbi:11757">mouse mammary tumor virus</span>
###xml 235 239 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 309 313 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
Infection by human papillomavirus (HPV) is the major risk factor for uterine cervix cancer and for a subset of head and neck squamous cell carcinomas (HNSCC). HPV, Epstein Barr virus (EBV) and sequences from mouse mammary tumor virus (MMTV) have been detected in breast tumors, and the presence of integrated SV40 T/t antigen in breast carcinomas correlates with an aggressive phenotype and poor prognosis.
###end p 4
###begin p 5
###xml 145 151 145 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNASEL</italic>
A genetic predisposition could explain why some viral infections persist and induce cancer, while others disappear spontaneously. This points at RNASEL as a strong susceptibility gene.
###end p 5
###begin title 6
Methodology/Principal Findings
###end title 6
###begin p 7
###xml 780 786 780 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNASEL</italic>
###xml 1367 1369 1367 1369 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 181 189 <span type="species:ncbi:9606">patients</span>
###xml 292 300 <span type="species:ncbi:9606">patients</span>
###xml 319 322 <span type="species:ncbi:10566">HPV</span>
###xml 415 418 <span type="species:ncbi:10566">HPV</span>
###xml 492 500 <span type="species:ncbi:9606">patients</span>
###xml 547 550 <span type="species:ncbi:10566">HPV</span>
###xml 597 605 <span type="species:ncbi:9606">patients</span>
###xml 683 691 <span type="species:ncbi:9606">patients</span>
###xml 966 974 <span type="species:ncbi:9606">patients</span>
###xml 1001 1009 <span type="species:ncbi:9606">patients</span>
###xml 1067 1075 <span type="species:ncbi:9606">patients</span>
###xml 1317 1325 <span type="species:ncbi:9606">patients</span>
To evaluate the implication of an abnormal activity of RNase L in the onset and development of viral induced cancers, the study was initiated by searching for germline mutations in patients diagnosed with uterine cervix cancer. The rationale behind is that close to 100% of the cervix cancer patients have a persistent HPV infection, and if a defective RNase L were responsible for the lack of ability to clear the HPV infection, we would expect to find a wide spectrum of mutations in these patients, leading to a decreased RNase L activity. The HPV genotype was established in tumor DNA from 42 patients diagnosed with carcinoma of the uterine cervix and somatic tissue from these patients was analyzed for mutations by direct sequencing of all coding and regulatory regions of RNASEL. Fifteen mutations, including still uncharacterized, were identified. The genotype frequencies of selected single nucleotide polymorphisms (SNPs) established in the cervix cancer patients were compared between 382 patients with head and neck squamous cell carcinomas (HNSCC), 199 patients with primary unilateral breast cancer and 502 healthy Danish control individuals. We found that the genotype frequencies of only one of the 15 mutations, the yet uncharacterized 5'UTR mutation rs3738579 differed significantly between cancer patients and control individuals (P-value: 4.43x10-5).
###end p 7
###begin title 8
Conclusion/Significance
###end title 8
###begin p 9
###xml 124 130 124 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNASEL</italic>
###xml 270 276 270 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNASEL</italic>
###xml 171 179 <span type="species:ncbi:9606">patients</span>
In conclusion, we have discovered an increased risk, a heterozygous advantage and thereby a protective effect linked to the RNASEL SNP rs3738579. This effect is found for patients diagnosed with carcinoma of the uterine cervix, HNSCC, and breast cancer thus pointing at RNASEL as a general marker for cancer risk and not restricted to familial prostate cancer.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNASEL</italic>
###xml 336 339 336 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Zhou1">[1]</xref>
###xml 340 343 340 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Roy1">[5]</xref>
Ribonuclease L (RNASEL) encoding the versatile endoribonuclease RNase L is a key enzyme in the interferon induced antiviral and anti-proliferate pathway, involved in cellular viral defense, single-stranded RNA cleavage and tumor suppressor activities as stress mediated apoptosis, cell proliferation and regulation of protein synthesis [1]-[5].
###end p 11
###begin p 12
###xml 200 203 200 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Hovanessian1">[6]</xref>
###xml 205 208 205 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Kerr1">[7]</xref>
###xml 444 447 444 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Naik1">[8]</xref>
RNase L is activated in response to viral infection and the presence of virally encoded dsRNA mobilizes the type I interferons (IFN), which activate a family of 2'-5' oligoadenylate synthetases (OAS) [6], [7]. With ATP as substrate these enzymes produce 5'-phosphorylated 2'-5' linked oligoadenylates (2-5A), which activate RNase L by binding to the ankyrin repeats and inducing dimerization, essential for the endonuclease activity of RNase L [8].
###end p 12
###begin p 13
###xml 426 429 426 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Dong1">[9]</xref>
###xml 431 435 431 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Tanaka1">[10]</xref>
###xml 578 582 578 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Manning1">[11]</xref>
###xml 734 738 734 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Dong2">[12]</xref>
###xml 871 875 871 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Casey1">[13]</xref>
###xml 1052 1056 1052 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Dong2">[12]</xref>
###xml 1249 1253 1249 1253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Liu1">[14]</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human RNase L comprises 741 amino acids, and three different domains, a nine ankyrin repeat in the N-terminal, a kinase-like and an RNase domain in the C-terminal part. The ankyrin repeats are known to be involved in protein/protein interactions, but the RNase L ankyrin repeats (2 to 4) bind the 2-5A molecule, which initiates the conformational change of RNase L leading to dimerization and thereby activation of the enzyme [9], [10]. Based upon sequence comparison it is predicted that RNase L should have protein kinase activity, but it has not been experimentally verified [11]. However, two missense mutations (R462Q and K392R) located in the protein kinase region have been shown to affect the enzyme dimerization and activity [12]. R462Q is a frequent and well-characterized mutation and homozygosity for the rare allele reduces the activity of RNase L by 3 fold [13]. K392R, located in the protein kinase-like region II and implicated in binding of ATP in kinases, prevents the dimerization of RNase L and thereby the activation of the enzyme [12]. The kinase-like and ribonuclease domains are related to those found in IRE 1, a transmembrane serine/threonine protein kinase receptor involved in the response to unfolded proteins in the ER [14].
###end p 13
###begin p 14
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNASEL</italic>
###xml 183 187 183 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Patmore1">[15]</xref>
###xml 198 202 198 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Halder1">[16]</xref>
###xml 307 311 307 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Hoglund1">[17]</xref>
RNASEL is located within the hereditary prostate cancer 1 (HPC1) region at 1q25.3. Chromosomal gain comprising this region has been found as a frequent event in uterine cervix cancer [15] and HNSCC [16] and amplification of the entire chromosome arm 1q is considered an early event in breast carcinogenesis [17].
###end p 14
###begin p 15
###xml 22 28 22 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNASEL</italic>
###xml 126 130 126 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Carpten1">[18]</xref>
###xml 428 432 428 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Carpten1">[18]</xref>
###xml 574 577 574 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Zhou1">[1]</xref>
###xml 692 696 692 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Carpten1">[18]</xref>
###xml 809 813 809 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Rokman1">[19]</xref>
###xml 933 937 933 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Rennert1">[20]</xref>
###xml 1279 1282 1279 1282 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1293 1296 1293 1296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Xiang1">[3]</xref>
###xml 387 395 <span type="species:ncbi:9606">patients</span>
###xml 569 573 <span type="species:ncbi:10090">mice</span>
###xml 1266 1271 <span type="species:ncbi:10090">mouse</span>
Germline mutations in RNASEL segregate with the disease in prostate cancer families with linkage to the HPC1 region at 1q25.3 [18]. The majority of missense mutations are found within exon 2 encoding the ankyrin repeats and part of the kinase-like domain. Cells from carriers of M1I and E265X showed half the normal activity of RNase L and the normal allele was lost in tumor cells from patients heterozygous for these muations [18]. E265X terminates translation within the 2-5A binding domain of RNase L, a similar mutation has been shown to eliminate 2-5A binding in mice [1]. The mutation was originally identified in four brothers, three of which suffered from aggressive prostate cancer [18]. Carriers of E265X develop prostate cancer on an average of 11 years before non-carriers from the same families [19]. A founder mutation 471delAAAG, resulting in a truncated protein, is associated with prostate cancer in Ashkenazi Jews [20]. A number of missense mutations are found in hereditary prostate cancer (HPC) families as: G59S, I97L, I220V, S406F, R462Q, Y529C and D541E, no mis- or nonsense mutations have been found in the ribonuclease domain. The mutations G59S, I97L, I220V, G296V, S322F, Y529C and D541E showed normal level of RNase L when measured in a mouse RNase L-/- cell line [3].
###end p 15
###begin p 16
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNASEL</italic>
###xml 182 186 182 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Li1">[21]</xref>
###xml 210 216 210 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNASEL</italic>
###xml 558 562 558 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Li1">[21]</xref>
###xml 684 688 684 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Nakazato1">[22]</xref>
###xml 822 826 822 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Casey1">[13]</xref>
###xml 828 832 828 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Rokman1">[19]</xref>
###xml 834 838 834 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Wiklund1">[23]</xref>
###xml 840 844 840 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Wang1">[24]</xref>
###xml 507 510 <span type="species:ncbi:9606">men</span>
Due to the tumor suppressor activities of RNASEL it is suggested that RNase L directly or indirectly suppress one or more steps in the prostate tumorigenesis or metastasis formation [21]. Germline mutations in RNASEL have been intensively studied in sporadic and familial prostate cancer but the results are contradictive. Recently, a comprehensive meta-analysis comprising the mutations D541E, R462Q and E265X concluded that the genotype E541 increased the risk of developing prostate cancer for Caucasian men, regardless of a family history of the disease [21]. In contrast, E541 was found to increase the risk of prostate cancer in Japanese families with multiple affected members [22]. A marginal effect has been seen for E541 in the Swedish population but studies on other populations could not confirm these results [13], [19], [23], [24].
###end p 16
###begin p 17
###xml 183 186 183 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Xiang1">[3]</xref>
###xml 346 350 346 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Casey1">[13]</xref>
###xml 540 544 540 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Casey1">[13]</xref>
###xml 427 430 <span type="species:ncbi:9606">men</span>
R462Q is located in the kinase-like domain, and the R462Q variant is capable of binding 2-5A, with a reduced ability to dimerize, a configuration necessary for the enzymatic activity [3]. The catalytic activity of the mutant enzyme is decreased three fold when compared to the wild type RNase L, and it is no longer capable of inducing apoptosis [13]. Males heterozygous for R462Q have a 1.5-fold elevated risk, and homozygous men double the risk of developing prostate cancer, suggesting R462Q to be a predictive marker for the malignancy [13].
###end p 17
###begin p 18
###xml 128 134 128 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNASEL</italic>
###xml 285 289 285 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Wiklund1">[23]</xref>
###xml 291 295 291 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Maier1">[25]</xref>
###xml 537 541 537 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Rokman1">[19]</xref>
###xml 543 547 543 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Rennert2">[26]</xref>
###xml 708 712 708 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Rennert2">[26]</xref>
###xml 806 810 806 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Rennert2">[26]</xref>
###xml 412 416 <span type="species:ncbi:9319">Euro</span>
###xml 661 665 <span type="species:ncbi:9319">Euro</span>
###xml 676 684 <span type="species:ncbi:9606">patients</span>
Association between the R462Q carriers and risk of developing prostate cancer seems to depend highly on ethnicity. Mutations in RNASEL are found at a very low rate in the German and Swedish population, and no significant association was found between R462Q and risk of prostate cancer [23], [25]. Homozygosity for 462Q was significantly more frequent in Finnish prostate cancer families than in controls, and in Euro-Americans with a family history of prostate cancer, R462Q was inversely associated with low grade and low stage disease [19], [26]. A significant association was found between R462Q and an increased risk of early-stage and low-grade disease in Euro-Americans patients with no family history [26]. In Afro-Americans R462Q was associated with a positive family history and high-grade tumors [26].
###end p 18
###begin p 19
###xml 153 157 153 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Bartsch1">[27]</xref>
###xml 256 260 256 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Kruger1">[28]</xref>
###xml 337 341 337 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Sevinc1">[29]</xref>
###xml 458 462 458 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Urisman1">[30]</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 490 498 <span type="species:ncbi:9606">patients</span>
###xml 665 673 <span type="species:ncbi:9606">patients</span>
###xml 739 760 <span type="species:ncbi:11786">murine leukemia virus</span>
###xml 762 766 <span type="species:ncbi:11786">XMLV</span>
###xml 790 798 <span type="species:ncbi:9606">patients</span>
Patients with a familial pancreatic cancer, which are homozygous for 462Q, presented a more aggressive disease with a high risk of developing metastasis [27] and the genotype is associated with age of onset of hereditary non-polyposis colon cancer (HNPCC) [28]. No association was found between breast cancer risk and any R462Q genotype [29]. Recently, a strong link was established between impaired RNase L activity and infection by a novel gammaretrovirus [30]. cDNA from prostate cancer patients with different genotypes for R462Q, were used to screen an oligonucleotide array containing the most conserved sequences from all known viruses. Forty percent of the patients homozygous for 462Q were found to be infected by the xenotrophic murine leukemia virus (XMLV), whereas only 1.5% of patients being heterozygous and homozygous (RR) carried the virus. Cells, homozygous for Q have a decreased RNase L catalytic activity and loose the ability to go into apoptosis, strongly indicating that RNase L plays a role in clearing viral infection.
###end p 19
###begin p 20
###xml 253 257 253 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Parkin1">[31]</xref>
###xml 55 58 <span type="species:ncbi:10566">HPV</span>
###xml 117 122 <span type="species:ncbi:9606">women</span>
###xml 190 193 <span type="species:ncbi:10566">HPV</span>
###xml 247 252 <span type="species:ncbi:9606">women</span>
It is estimated that 80% of all adults will acquire an HPV infection at some point of their life. Worldwide, 500,000 women are diagnosed with cervical cancer and the prevalence of a genital HPV infection is estimated to be 326 million among adult women [31].
###end p 20
###begin p 21
###xml 110 114 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Parkin1">[31]</xref>
###xml 267 271 267 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Ragin1">[32]</xref>
###xml 143 150 <span type="species:ncbi:4097">tobacco</span>
###xml 190 193 <span type="species:ncbi:10566">HPV</span>
HNSCC is the sixth most frequent cancer form with 650,000 new incidents and 350,000 deaths per year worldwide [31]. The major risk factors are tobacco and alcohol consumption, body mass and HPV infection, the latter is especially associated with oropharyngeal cancer [32].
###end p 21
###begin p 22
###xml 164 168 164 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Kamangar1">[33]</xref>
###xml 302 306 302 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Lilienfeld1">[34]</xref>
###xml 308 312 308 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Henderson1">[35]</xref>
###xml 85 90 <span type="species:ncbi:9606">women</span>
Breast Cancer is the second most frequent cancer in the world and the most common in women with more than 1 million new cases and more than 411,000 deaths per year [33]. The major risk factors are age, early menarche, late age of first pregnancy, late menopause, hormone exposure, and lack of exercise [34], [35].
###end p 22
###begin p 23
###xml 57 61 57 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-zurHausen1">[36]</xref>
###xml 126 130 126 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Kreimer1">[37]</xref>
###xml 251 255 251 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Hobbs1">[38]</xref>
###xml 333 337 333 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-An1">[39]</xref>
###xml 427 431 427 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Kreimer1">[37]</xref>
###xml 635 639 635 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Kubbutat1">[40]</xref>
###xml 641 645 641 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Thomas1">[41]</xref>
###xml 0 3 <span type="species:ncbi:10566">HPV</span>
###xml 261 264 <span type="species:ncbi:10566">HPV</span>
###xml 342 345 <span type="species:ncbi:10566">HPV</span>
###xml 433 436 <span type="species:ncbi:10566">HPV</span>
HPV is the major risk factor for uterine cervical cancer [36] and responsible for approximately one fourth of the HNSCC cases [37]. The highest prevalence is found for squamous cell carcinomas (SCC) located at the tonsils, oropharynx, oral and larynx [38]. The HPV strains 16 and 18 are associated with 99.7% of all cervical cancers [39] and HPV-16 with 86.7% of oropharyngeal SSC, 68.2% of oral SSC and 69.2% of laryngeal SSC [37]. HPV-16 and 18 are among the high-risk viruses, encoding the oncoproteins E6 and E7, which are capable of silencing p53 and pRb, respectively. Thereby, they are omitting important cell cycle checkpoints [40], [41].
###end p 23
###begin p 24
###xml 77 81 77 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-DiLonardo1">[42]</xref>
###xml 222 226 222 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Choi1">[43]</xref>
###xml 445 449 445 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Theodorou1">[44]</xref>
###xml 597 601 597 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Lawson1">[45]</xref>
###xml 45 48 <span type="species:ncbi:10566">HPV</span>
###xml 164 167 <span type="species:ncbi:10566">HPV</span>
###xml 245 270 <span type="species:ncbi:11757">mouse mammary tumor virus</span>
###xml 272 276 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 338 343 <span type="species:ncbi:9606">human</span>
###xml 487 492 <span type="species:ncbi:9606">human</span>
###xml 520 541 <span type="species:ncbi:11901">bovine leukemia virus</span>
###xml 543 546 <span type="species:ncbi:11901?0.9251269035532995">BLV</span>
Di Lonardo et al. were the first to identify HPV-16 DNA in breast carcinomas [42]. Worldwide studies show a considerable geographic difference in the prevalence of HPV in breast carcinomas varying from 0-86%, described in [43]. In addition, the mouse mammary tumor virus (MMTV) has been found in breast tumors, and insertion sites in the human genome affects genes, which are part of gene families and pathways involved in breast carcinogenesis [44]. Likewise, Epstein Barr virus (EBV), human herpes virus-8 (HHV-8) and bovine leukemia virus (BLV) have been detected in breast tumors, reviewed in [45].
###end p 24
###begin p 25
The majority of viral infections are cleared by the immune system, and a genetic predisposition could explain why the infection persists and induce cancer in some individuals.
###end p 25
###begin p 26
###xml 108 114 108 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNASEL</italic>
###xml 199 202 <span type="species:ncbi:10566">HPV</span>
The aim of this study was to establish a specific genotype or a combination of genotypes (haplotype) across RNASEL, which could prove to be a marker for the individual risk of acquiring a persistent HPV infection, thereby an increasing risk of developing especially uterine cervix and head and neck cancer. The promoter region and the 5' and 3' UTR were included in the search for new mutations. A yet uncharacterized 5'UTR mutation, being in linkage disequilibrium (LD) with well characterized missense mutations in exon 2, proved to be a statistical strong marker for increased risk and heterozygous protection from all three cancer forms.
###end p 26
###begin title 27
Results and Discussion
###end title 27
###begin title 28
###xml 23 29 23 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNASEL</italic>
Mutational spectrum of RNASEL in cervical carcinomas
###end title 28
###begin p 29
###xml 509 515 509 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNASEL</italic>
###xml 197 205 <span type="species:ncbi:9606">patients</span>
###xml 354 362 <span type="species:ncbi:9606">patients</span>
###xml 521 524 <span type="species:ncbi:10566">HPV</span>
As viral infection is implicated in close to 100% of all uterine cervix cancer cases, we hypothesized that if a defective RNase L is responsible for the lack of ability to clear a viral infection, patients with cervix cancer would carry a wide spectrum of mutations affecting the activity or expression level of RNase L. Therefore, leukocyte DNA from 42 patients diagnosed with uterine cervix cancer were screened for mutations by direct sequencing of both DNA strands of all coding and regulatory regions of RNASEL. The HPV genotype was established on DNA isolated from each tumor.
###end p 29
###begin p 30
###xml 170 178 170 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002492-g001">Figure 1</xref>
We identified 15 different mutations: four non-synonymous (I97L, F364L, R462Q and D541E), one nonsense (E265X), one synonymous (K724K) and nine in un-translated regions (Figure 1).
###end p 30
###begin title 31
###xml 94 100 94 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNASEL</italic>
###xml 223 230 223 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002492-t003">table 3</xref>
###xml 172 180 <span type="species:ncbi:9606">patients</span>
The entire coding and flanking intron sequences, the 5' and 3' UTR and the promoter region of RNASEL were analyzed for mutations by direct sequencing of leukocyte DNA from patients with cervix cancer (primers are listed in table 3).
###end title 31
###begin p 32
The two well-described exonic SNPs (rs627928 and K724K) are not illustrated. Genotype frequencies of the SNPs determined in the controls are given beneath the illustration of each SNP, along with a P-value of the marginal effect of the SNP. The Bonferroni corrected significance level is 0.05/12 = 0.004. The genotype frequencies of the cases in the remaining 3 SNPs are: rs627928-7:20:13 (G/G:G/T:T/T); A-T In5-26:13:0 (A/A:A/T:T/T) and K724K-37:3:0 (A/A:A/G:G/G). The ideogram color code is defined as: white, coding region; grey, UTR; black, intragenic regions.
###end p 32
###begin p 33
###xml 274 278 274 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Silverman1">[46]</xref>
###xml 280 284 280 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Liang1">[47]</xref>
###xml 746 750 746 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Li2">[48]</xref>
###xml 841 847 841 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NGN1/3</italic>
###xml 931 935 931 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOD</italic>
###xml 975 979 975 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Zhou2">[49]</xref>
The mutations of I97L and E265X are positioned in the ankyrin repeat three and seven, respectively, and F364L, R462Q and D541E are part of the kinase-like domain. No mis- or nonsense mutations were found in the RNase domain in consistency with previous reports (reviewed in [46], [47]). One highly polymorphic T to C mutation (rs3738579) was present in 5'UTR of exon 2, 95 bp upstream from the translation initiation codon. The intron mutations comprised rs12742422, an A>G, 59 bp from the 5' splice site in intron 2 and A>T In5, an A to T 34 bp from the 3' splice site in intron 5. The four mutations in the 3'UTR comprised rs12135247, rs104825, rs11072 and rs1048260. None of these were located in any of the characterized regulatory sequences [48]. Mutations in the promoter region comprised rs7534480 within the Neurogenin binding site (NGN1/3) and rs6690434, a highly conserved residue within the myoblast-determining factor (MYOD), the positions given are according to [49].
###end p 33
###begin p 34
###xml 348 355 <span type="species:ncbi:9606">patient</span>
Non-synonymous and nonsense mutations with the exception of F364L, reported here for the first time, have previously been characterized with specific focus on familial and sporadic prostate cancer. F364L is located on the border of the protein kinase-like domain and no implication of F364L on the activity of RNase L has yet been established. One patient was heterozygous for F364L, whereas none was found among 407 controls in the current study.
###end p 34
###begin p 35
###xml 106 114 106 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002492-g001">Figure 1</xref>
###xml 26 34 <span type="species:ncbi:9606">patients</span>
None of the cervix cancer patients were homozygous for any of the rare alleles of the intronic mutations (Figure 1). It is not known whether any of these mutations affect the translation or the splicing efficiency.
###end p 35
###begin p 36
###xml 88 94 88 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNASEL</italic>
###xml 127 131 127 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n&#8202;=&#8202;</italic>
###xml 260 268 260 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002492-g001">Figure 1</xref>
We established the genotype frequencies of twelve out of the fifteen mutations found in RNASEL in a Danish control population (n = 502) using the primer extension method. The number of successfully genotyped controls varies according to the specific mutation (Figure 1).
###end p 36
###begin title 37
Comparison of genotype frequencies in different cohorts
###end title 37
###begin p 38
###xml 118 126 118 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002492-g001">Figure 1</xref>
###xml 770 774 770 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Casey1">[13]</xref>
###xml 776 780 776 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Bartsch1">[27]</xref>
###xml 840 846 840 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNASEL</italic>
###xml 1034 1038 1034 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Bisbal1">[50]</xref>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
###xml 332 340 <span type="species:ncbi:9606">patients</span>
###xml 413 421 <span type="species:ncbi:9606">patients</span>
The genotype frequencies were compared between the cervix cancer patients and the controls using Fisher's exact test (Figure 1). The frequencies of SNP rs3738579 were found to differ most in the two groups (P-value: 0.086), but none of the SNPs showed significant differences. Subsequently, we investigated three SNPs in 199 Danish patients diagnosed with primary unilateral breast cancer and in 382 Danish HNSCC patients. SNP rs3738579 was chosen because it showed the most deviating frequencies; SNP R462Q because it is known to affect the RNase L activity, where the genotypes GA or AA are associated with a decrease in RNase L activity, reduced ability to clear viral infections, linked to familial prostate cancer, and to more advanced disease in pancreatic cancer [13], [27]; SNP rs6690434, which is located in the promoter region of RNASEL affecting a potential MyoD binding site, could be of possible regulatory importance. RNase L has been found to regulate MyoD mRNA stability and to be involved in myoblast differentiation [50].
###end p 38
###begin p 39
###xml 190 198 <span type="species:ncbi:9606">patients</span>
###xml 251 259 <span type="species:ncbi:9606">patients</span>
###xml 283 291 <span type="species:ncbi:9606">patients</span>
Random samples were sequenced to verify the genotypes, established by the primer extension method, of each SNP (rs3738579, SNP R462Q and rs6690434). In total, samples from all cervix cancer patients, 47% (239/504) controls, 34% (62/185) breast cancer patients and 13% (47/375) HNSCC patients were sequenced to verify the interpretation of the genotypes.
###end p 39
###begin title 40
The implication of the 5'UTR SNP rs3738579 in viral and non-viral induced cancer
###end title 40
###begin p 41
###xml 51 59 <span type="species:ncbi:9606">patients</span>
The genotype frequencies for each sample of cancer patients (breast and HNSCC) were compared to the controls. A significant difference was seen only for rs3738579 in breast cancer, P-value = 0.0012 and in HNSCC, P-value = 0.0006.
###end p 41
###begin p 42
###xml 133 137 133 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-1">[51]</xref>
###xml 219 226 219 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002492-t001">Table 1</xref>
###xml 381 383 381 383 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 409 415 409 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNASEL</italic>
We found that the genotype frequencies for rs3738579 were similar in our control population and the HapMap European (CEU) population [51], as opposed to the genotype frequencies in the three similar cancer cohorts (see Table 1). Interestingly, a combination of data from all three cancer forms provided strong statistical evidence for rs3738579 as a cancer marker (P-value: 4.43x10-5). This finding points to RNASEL as a general marker for cancer risk being not exclusively linked to viral induced cancer forms. In addition, heterozygous individuals were overrepresented in the controls, implying a heterozygote advantage and potential protection against the three cancer forms.
###end p 42
###begin title 43
Genotype frequencies for SNP rs3738579
###end title 43
###begin p 44
The genotype frequencies are given for controls, n = 502, the CEU HapMap population, n = 60 cervix cancer, n = 42, breast cancer, n = 199 and HNSCC, n = 382, respectively, and the proportion of individuals with the genotype is given as percent in brackets. The genotype frequencies of the controls and the HapMap population are similar (P-value: 0.95), and the genotype frequencies of the three cancer populations are similar (P-value for cervix and breast: 0.18; cervix and head and neck: 0.41; breast and head and neck: 0.48).
###end p 44
###begin p 45
Considering pairs of SNPs, none of the pairs show an association with any of the three types of cancer, or all jointly, stronger than the marginal association with rs3738579, indicating that rs3738579 is a better marker than any combination of two SNPs.
###end p 45
###begin p 46
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002492-t002">Table 2</xref>
Table 2 shows odds ratios (ODs) for the three different genotypes of rs3738579; overall the ODs are similar for the three types of cancer.
###end p 46
###begin title 47
Odds Ratio for the SNP rs3738579 in the three cancer samples and in the samples combined, compared to the control population.
###end title 47
###begin title 48
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNASEL</italic>
Linkage disequilibrium (LD) across RNASEL
###end title 48
###begin p 49
###xml 355 361 355 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNASEL</italic>
###xml 435 443 435 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002492-g002">Figure 2</xref>
###xml 894 902 <span type="species:ncbi:9606">patients</span>
To our knowledge the implication of rs3738579 on activity or expression of RNase L is unknown. The mutation is not located within a uORF (un-translated open reading frame) but may change the conformation of the mRNA. One explanation could be that rs3738579 is in linkage disequilibrium (LD) with a not yet identified mutation in the regulatory regions of RNASEL or a causative mutation in a nearby gene within the same haploblock (see Figure 2). The LD pattern across the sequenced region for the control population was calculated. Two independent LD blocks were found, one in the 3'UTR region and one in the region spanning the promoter region and exon 2. If a causative mutation exists, being in LD with rs3738579, it can only be present upstream from the introns flanking exon 2, since all exons, flanking intron and promoter sequences have been directly sequenced in all 42 cervical cancer patients.
###end p 49
###begin title 50
###xml 58 65 58 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNASEL.</italic>
Linkage Disequilibrium (LD)-plot of the region containing RNASEL.
###end title 50
###begin p 51
###xml 331 335 331 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Barrett1">[54]</xref>
Each square indicates the level of LD between two SNPs. The color code is defined as: red (high LD), LOD(2 and D' = 1; shades of pink/red, LOD(2 and D'<1; blue, LOD<2 and D' = 1; white, LOD<2 and D'<1. The top of the figure shows the genomic position and the known genes in the region (yellow: exon; grey: UTR; black line: intron) [54]. Note that exon 1 is not shown. The two SNPs within the promoter are illustrated to the far right.
###end p 51
###begin p 52
###xml 359 363 359 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Urisman1">[30]</xref>
###xml 94 98 <span type="species:ncbi:11786">XMLV</span>
###xml 166 174 <span type="species:ncbi:9606">patients</span>
###xml 227 235 <span type="species:ncbi:9606">patients</span>
###xml 288 292 <span type="species:ncbi:11786">XMLV</span>
###xml 328 336 <span type="species:ncbi:9606">patients</span>
A heterozygous advantage was found in the study linking infection by a novel gammaretrovirus (XMLV) to the R462Q genotypes. Here, 40% of the analyzed prostate cancer patients, being homozygous for the Q allele, and 1.9% of the patients being homozygous for the R allele, were infected by XMLV. None of the analyzed heterozygous patients carried the infection [30]. This mutation is in LD with rs3738579, where the heterozygous genotypes of both SNPs are linked as well as homozygosity for the rare and frequent alleles, respectively.
###end p 52
###begin title 53
###xml 21 24 <span type="species:ncbi:10566">HPV</span>
Establishment of the HPV genotype
###end title 53
###begin p 54
###xml 495 503 495 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002492-g003">Figure 3</xref>
###xml 4 7 <span type="species:ncbi:10566">HPV</span>
###xml 97 100 <span type="species:ncbi:10566">HPV</span>
###xml 208 211 <span type="species:ncbi:10566">HPV</span>
###xml 293 296 <span type="species:ncbi:10566">HPV</span>
###xml 440 443 <span type="species:ncbi:10566">HPV</span>
###xml 485 493 <span type="species:ncbi:9606">patients</span>
###xml 663 666 <span type="species:ncbi:10566">HPV</span>
The HPV genotype was established in DNA isolated from cervical carcinomas using the Linear Array HPV Genotyping Test kit (Roche Diagnostics GmbH, Mannheim, Germany), which allow for detection of 37 different HPV genotypes including 13 from the high-risk group. We found no correlation between HPV strains and rs3738579 genotypes. All cervical tumor samples were infected with HPV16 and in addition 52% with HPV18, in total eleven different HPV strains were identified in the 42 cervix patients (Figure 3). In comparison, HNSCC is a highly heterogeneous disease with predominantly squamous cell carcinomas and only 30% of the study sample was expected to carry an HPV infection. This strengthens the hypothesis presented here that RNase L may be a general marker for cancer risk and not specifically linked to viral induced cancers.
###end p 54
###begin title 55
###xml 16 19 <span type="species:ncbi:10566">HPV</span>
Distribution of HPV genotypes in cervical carcinomas.
###end title 55
###begin p 56
###xml 64 67 <span type="species:ncbi:10566">HPV</span>
Thirty-two uterine cervix tumors were infected by more than one HPV strain and all 42 cases were infected by the high-risk HPV16.
###end p 56
###begin title 57
Conclusion
###end title 57
###begin p 58
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNASEL</italic>
A heterozygote advantage and protective potential of RNASEL have not previously been reported. SNP rs3738579 is located within the 5'UTR region and may be implicated in posttranscriptional regulation or a mediator of an existing low penetrant mutation. One such mutation could be the R462Q located within the same exon. 462Q decreases the activity of RNase L up to three fold and has been intensively studied in large prostate cancer cohorts, but the results are highly contradictive. Linkage to rs3738579 may help explain these diverse results.
###end p 58
###begin p 59
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNASEL</italic>
###xml 264 272 <span type="species:ncbi:9606">patients</span>
Interestingly, the implication of a mutated RNASEL on viral induced cervical cancer has not been described before, despite the well-documented role of the enzyme in the degradation of viral RNA. Furthermore, characterization of the new 5'UTR mutation rs3738579 in patients with sporadic breast and HNSCC led to the hypothesis that RNase L is a general marker for cancer risk, not restricted to familial prostate cancer.
###end p 59
###begin title 60
Materials and Methods
###end title 60
###begin title 61
###xml 14 22 <span type="species:ncbi:9606">patients</span>
Cervix cancer patients
###end title 61
###begin p 62
###xml 104 112 <span type="species:ncbi:9606">patients</span>
###xml 212 217 <span type="species:ncbi:9606">women</span>
###xml 266 271 <span type="species:ncbi:9606">women</span>
###xml 285 292 <span type="species:ncbi:4097">tobacco</span>
Pre-treatment buffy coat blood samples, (n = 40) and tumor tissue samples, (n = 42) were collected from patients with newly diagnosed carcinoma of the uterine cervix. Median age was 59 (range 28-84). Twenty-nine women were postmenopausal, 12 premenopausal. Nineteen women were current tobacco smokers and smoking history was not available in five cases. Tumors were FIGO stage IB, n = 4; IIA, n = 1; IIB, n = 20; IIIa, n = 2 and IIIIB, n = 15. The majority of tumors were squamous cell carcinoma, n = 37 while one was an adenocarcinoma, one mixed adeno/neuroendocrine and 3 were adenosquamous carcinoma.
###end p 62
###begin title 63
###xml 59 62 <span type="species:ncbi:10566">HPV</span>
DNA preparation from fresh frozen cervix cancer tissue for HPV analysis
###end title 63
###begin p 64
###xml 121 124 <span type="species:ncbi:10566">HPV</span>
DNA was isolated from 42 fresh frozen tumor tissues according to the manufacturers' recommendations for the Linear Array HPV Genotyping Test kit (Roche Diagnostics GmbH, Mannheim, Germany). In brief, the tissue was dissolved in 250 mul PBS, 80 mul tissue lysis buffer (ALT) and 20 mul Proteinase K, mixed/vortexed briefly and incubated for 60 min at 56degreesC. 250 mul lysis buffer (AL) containing carrier RNA was added, mixed and incubated at 70degreesC for 30 min. 300 mul 96% ethanol was added, the solutions were mixed thoroughly and incubated for 5 min at room temperature. The tubes were briefly centrifuged and all liquid transferred to a QlAamp column, the lysate was removed by a vacuum pump, 750 mul wash buffer (AW2) was added and left for 1 min. The wash buffer was removed and the samples washed with 750 mul 96% ethanol. The filter from the column was transferred to a new tube. 120 mul elution buffer was added and collected by centrifugation after 2 min incubation at room temperature.
###end p 64
###begin p 65
The samples can be stored at 2-8degreesC for 7 days or at 20degreesC for 8 weeks.
###end p 65
###begin p 66
DNA was purified according to standard procedures.
###end p 66
###begin title 67
Control population
###end title 67
###begin p 68
###xml 175 179 175 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Hansen1">[52]</xref>
DNA was extracted from peripheral blood according to a modified salt precipitation method from 502 Danish medical students of both sexes in their first year at Medical school [52]. The Local Ethical Committee, Aarhus County, Denmark, approved the current study. All individuals were informed and consented both verbally and in writing.
###end p 68
###begin title 69
###xml 14 22 <span type="species:ncbi:9606">patients</span>
Breast cancer patients
###end title 69
###begin p 70
###xml 313 317 313 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Hansen2">[53]</xref>
###xml 416 420 416 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Hansen1">[52]</xref>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
###xml 93 101 <span type="species:ncbi:9606">patients</span>
Matching blood and tumor samples were collected from 199 primary breast cancer patients. All patients had primary unilateral breast carcinoma without evidence of disseminated disease, no other malignancies. Complete clinical, histopatological and biological information were available, the cohort is described in [53]. Purification of DNA was carried out using a modified salt precipitation protocol as described in [52].
###end p 70
###begin title 71
###xml 21 29 <span type="species:ncbi:9606">patients</span>
Head and Neck cancer patients
###end title 71
###begin p 72
###xml 71 79 <span type="species:ncbi:9606">patients</span>
###xml 138 146 <span type="species:ncbi:9606">patients</span>
DNA was derived from fibroblast cultures obtained from 382 consecutive patients with HNSCC treated at the Aarhus University Hospital. The patients were treated with primary radiotherapy according to the protocols and guidelines from the Danish Head and Neck Cancer Group (). The primary tumor sites were larynx, oropharynx, hypopharynx, nasopharynx and oral cavity.
###end p 72
###begin title 73
Ethical approval
###end title 73
###begin p 74
###xml 85 93 <span type="species:ncbi:9606">patients</span>
The Local Ethical Committee, Aarhus County, Denmark, approved the current study. All patients were informed and consented both verbally and in writing.
###end p 74
###begin title 75
Mutation analysis
###end title 75
###begin p 76
###xml 100 107 100 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002492-t003">table 3</xref>
Both strands of all DNA fragments were sequenced. Primer sequences and PCR conditions are listed in table 3. The initial standard PCR amplification comprised 20 ng DNA, 1 pmol of each primer, 250 muM dNTP (Roche), 1xbuffer (supplied with the enzyme) and 0.5 unit Taq polymerase (Roche) in a final volume of 25 mul.
###end p 76
###begin title 77
Primer sequences for DNA sequencing and SNP genotype assessment
###end title 77
###begin p 78
###xml 553 554 520 521 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
PCR cycle conditions were as follows: 1 cycle of 94degreesC for 4 min, 35 cycles of 93degreesC for 35 sec, 59degreesC for 40 sec, 72degreesC for 1 min followed by 72degreesC for 10 min. Products were analyzed by electrophoresis in a 1% agarose gel stained with ethidium bromide. Generation of a single stranded product for sequencing comprised: 2 mul PCR product from above, 5 pmol primer, 6 mul of a 2.5xbuffer (supplied with the BigDye kit, ABI, Foster City, CA) and 2 mul Reaction mix (BigDye ver. 2.0 and 1.1; ABI, Foster City, CA) supplied with ddH2O to a final volume of 20 mul. Conditions for cycle sequencing were as follows: 1 cycle of 96degreesC for 5 min, 25 cycles of 96degreesC for 30 sec, 59degreesC for 15 sec, 60degreesC for 4 min. The products were separated by capillary electrophoresis (ABI 3100, Applied Biosystems, Foster City, CA) and evaluated using the software Sequencing analysis(R) (Applied Biosystems, Foster City, CA).
###end p 78
###begin title 79
Single nucleotide polymorphism (SNP) detection
###end title 79
###begin p 80
###xml 150 157 150 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002492-t003">Table 3</xref>
The primer sequences for PCR amplification of the target region containing one or additional SNPs, and for detecting the individual SNP are listed in Table 3.
###end p 80
###begin p 81
###xml 177 178 176 177 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The PCR amplification comprised: 20 ng DNA, 200 muM dNTP, 0.4 Units Taq polymerase (Ampliqon, Bie and Berntsen, DK), 1xbuffer supplied with the enzyme and additional 1.6 mM MgCl2 in a final volume of 15 mul. Depending on the DNA fragment the annealing temperature was ranging between 54-60degreesC. The genotypes were determined by single nucleotide extension using the SNaPshot(R) kit following the manufacturers' instructions (Applied Biosystems, Foster City, CA). All products were detected via capillary electrophoresis using the software GeneMapper(R) (ABI 3100, Biosystems Solutions, Foster City, CA).
###end p 81
###begin title 82
###xml 0 3 <span type="species:ncbi:10566">HPV</span>
HPV detection
###end title 82
###begin p 83
###xml 17 20 <span type="species:ncbi:10566">HPV</span>
###xml 122 125 <span type="species:ncbi:10566">HPV</span>
###xml 203 206 <span type="species:ncbi:10566">HPV</span>
The Linear Array HPV Genotyping Test kit (Roche Diagnostics GmbH, Mannheim, Germany) allows for detection of 37 different HPV genotypes including 13 from the high-risk group. The differentiation between HPV genotypes is based upon PCR amplification of the highly polymorphic L1 region followed by hybridization to specific oligonucleotide probes and colorimetric detection. The manufacturers' guidelines were followed.
###end p 83
###begin title 84
Statistical methods
###end title 84
###begin p 85
A Bonferroni corrected Fisher's exact test is used for all tests. For cervical cancer 12 tests are for single marker associations, yielding a Bonferroni corrected significance level of 0.05/12 = 0.004, and 66 tests are made for SNP-pair associations yielding a corrected level of 0.05/66 = 0.0008. For breast cancer and HNSCC 3 tests are made for single marker associations, yielding a Bonferroni corrected significance level of 0.05/3 = 0.0167, and 3 tests are made for SNP-pair associations.
###end p 85
###begin p 86
Missing data are handled by omitting individuals with missing data in the genotype counts; e.g. all individuals with missing data in either rs3738579 or R462Q are omitted when calculating the genotype frequencies of that specific SNP-pair.
###end p 86
###begin p 87
###xml 22 23 22 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 26 27 26 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</italic>
###xml 33 34 33 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 35 36 35 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</italic>
###xml 44 45 44 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 164 165 164 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</italic>
ODs are calculated as p(1-q)/[(1-p)q] where p is the frequency of one of the three genotypes in the cancer samples (cervix, head and neck, breast, or combined) and q the frequency of the genotype in the control population.
###end p 87
###begin title 88
HapMap population
###end title 88
###begin p 89
###xml 186 190 186 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-1">[51]</xref>
The genotype frequencies for SNP rs3738579 in the European HapMap population are found by using the CEU population in the HapMap genome browser with HapMap data rel21a on NCBI build 35. [51]
###end p 89
###begin title 90
Linkage disequilibrium
###end title 90
###begin p 91
###xml 105 109 105 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002492-Barrett1">[54]</xref>
###xml 146 154 146 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002492-g002">Figure 2</xref>
Linkage disequilibrium (LD) is investigated by the program HaploView (v. 3.31) using genome build NCBI35 [54]. Only polymorphic SNPs are shown in Figure 2.
###end p 91
###begin p 92
T. Kjeldsen and E.L. Hein are greatly acknowledged for their excellent technical assistance.
###end p 92
###begin title 93
References
###end title 93
###begin article-title 94
Expression cloning of 2-5A-dependent RNAase: a uniquely regulated mediator of interferon action.
###end article-title 94
###begin article-title 95
A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon.
###end article-title 95
###begin article-title 96
Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2',5'-oligoadenylates.
###end article-title 96
###begin article-title 97
Caspase-dependent apoptosis by 2',5'-oligoadenylate activation of RNase L is enhanced by IFN-beta.
###end article-title 97
###begin article-title 98
A newly discovered function for RNase L in regulating translation termination.
###end article-title 98
###begin article-title 99
Synthesis of low molecular weight inhibitor of protein synthesis with enzyme from interferon-treated cells.
###end article-title 99
###begin article-title 100
pppA2'p5'A2'p5'A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells.
###end article-title 100
###begin article-title 101
RNase L dimerization in a mammalian two-hybrid system in response to 2',5'-oligoadenylates.
###end article-title 101
###begin article-title 102
Basis for regulated RNA cleavage by functional analysis of RNase L and Ire1p.
###end article-title 102
###begin article-title 103
###xml 68 73 <span type="species:ncbi:9606">human</span>
Structural basis for recognition of 2',5'-linked oligoadenylates by human ribonuclease L.
###end article-title 103
###begin article-title 104
###xml 37 42 <span type="species:ncbi:9606">human</span>
The protein kinase complement of the human genome.
###end article-title 104
###begin article-title 105
Alternative function of a protein kinase homology domain in 2', 5'-oligoadenylate dependent RNase L.
###end article-title 105
###begin article-title 106
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases.
###end article-title 106
###begin article-title 107
The protein kinase/endoribonuclease IRE1alpha that signals the unfolded protein response has a luminal N-terminal ligand-independent dimerization domain.
###end article-title 107
###begin article-title 108
Can a genetic signature for metastatic head and neck squamous cell carcinoma be characterised by comparative genomic hybridisation?
###end article-title 108
###begin article-title 109
A preliminary investigation of genomic screening in cervical carcinoma by comparative genomic hybridization.
###end article-title 109
###begin article-title 110
Multivariate analysis of chromosomal imbalances in breast cancer delineates cytogenetic pathways and reveals complex relationships among imbalances.
###end article-title 110
###begin article-title 111
Germline mutations in the ribonuclease L gene in families showing linkage with HPC1.
###end article-title 111
###begin article-title 112
###xml 75 83 <span type="species:ncbi:9606">patients</span>
Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer.
###end article-title 112
###begin article-title 113
A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews.
###end article-title 113
###begin article-title 114
RNASEL gene polymorphisms and the risk of prostate cancer: a meta-analysis.
###end article-title 114
###begin article-title 115
Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population.
###end article-title 115
###begin article-title 116
Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer.
###end article-title 116
###begin article-title 117
Analysis of the RNASEL gene in familial and sporadic prostate cancer.
###end article-title 117
###begin article-title 118
Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene.
###end article-title 118
###begin article-title 119
###xml 147 150 <span type="species:ncbi:9606">men</span>
Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men.
###end article-title 119
###begin article-title 120
RNASEL germline variants are associated with pancreatic cancer.
###end article-title 120
###begin article-title 121
Arg462Gln sequence variation in the prostate-cancer-susceptibility gene RNASEL and age of onset of hereditary non-polyposis colorectal cancer: a case-control study.
###end article-title 121
###begin article-title 122
Lack of association between RNASEL Arg462Gln variant and the risk of breast cancer.
###end article-title 122
###begin article-title 123
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant.
###end article-title 123
###begin article-title 124
Global cancer statistics, 2002.
###end article-title 124
###begin article-title 125
###xml 72 92 <span type="species:ncbi:10566">human papillomavirus</span>
Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis.
###end article-title 125
###begin article-title 126
Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.
###end article-title 126
###begin article-title 127
The age distribution in female breast and genital cancers.
###end article-title 127
###begin article-title 128
Hormonal carcinogenesis.
###end article-title 128
###begin article-title 129
Papillomaviruses and cancer: from basic studies to clinical application.
###end article-title 129
###begin article-title 130
###xml 0 20 <span type="species:ncbi:10566">Human papillomavirus</span>
Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review.
###end article-title 130
###begin article-title 131
###xml 0 20 <span type="species:ncbi:10566">Human papillomavirus</span>
Human papillomavirus and head and neck cancer: a systematic review and meta-analysis.
###end article-title 131
###begin article-title 132
###xml 14 34 <span type="species:ncbi:10566">human papillomavirus</span>
Prevalence of human papillomavirus DNA in various histological subtypes of cervical adenocarcinoma: a population-based study. Mod Pathol.
###end article-title 132
###begin article-title 133
###xml 4 7 <span type="species:ncbi:10566">HPV</span>
New HPV E6 binding proteins: dangerous liaisons?
###end article-title 133
###begin article-title 134
###xml 93 96 <span type="species:ncbi:10566">HPV</span>
Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation.
###end article-title 134
###begin article-title 135
###xml 0 20 <span type="species:ncbi:10566">Human papillomavirus</span>
Human papillomavirus in breast cancer.
###end article-title 135
###begin article-title 136
###xml 13 18 <span type="species:ncbi:9606">Human</span>
###xml 81 86 <span type="species:ncbi:9606">Women</span>
Detection of Human Papillomavirus DNA by DNA Chip in Breast Carcinomas of Korean Women.
###end article-title 136
###begin article-title 137
###xml 0 4 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer.
###end article-title 137
###begin article-title 138
###xml 12 17 <span type="species:ncbi:9606">human</span>
Viruses and human breast cancer.
###end article-title 138
###begin article-title 139
Implications for RNase L in prostate cancer biology.
###end article-title 139
###begin article-title 140
RNase L: its biological roles and regulation.
###end article-title 140
###begin article-title 141
Post-transcriptional regulation of RNase-L expression is mediated by the 3'-untranslated region of its mRNA.
###end article-title 141
###begin article-title 142
###xml 15 20 <span type="species:ncbi:9606">human</span>
Mapping of the human RNASEL promoter and expression in cancer and normal cells.
###end article-title 142
###begin article-title 143
The 2'-5' oligoadenylate/RNase L/RNase L inhibitor pathway regulates both MyoD mRNA stability and muscle cell differentiation.
###end article-title 143
###begin article-title 144
The International HapMap Project.
###end article-title 144
###begin article-title 145
Molecular genetic analysis of easily accessible breast tumour DNA, purified from the leftover from hormone receptor measurement.
###end article-title 145
###begin article-title 146
Allelic loss of 16q23.2-24.2 is an independent marker of good prognosis in primary breast cancer.
###end article-title 146
###begin article-title 147
Haploview: analysis and visualization of LD and haplotype maps.
###end article-title 147
###begin p 148
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 148
###begin p 149
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: Financial support was provided by The Danish Cancer Research Foundation, The Danish Medical Research Council, The Novo Nordic, The John and Birthe Meyer, The Boje Benzon, The Aarhus University Research and The A.P. Moller and Wife Foundations and Frits, Georg and Marie Cecilie Gluds grant. The Danish Cancer Society supported C.W.
###end p 149

